New Drug Approvals

MAY 9, 2025

Eligible participants had experienced disease progression on one or two prior lines of endocrine therapy , including one line with a CDK4/6 inhibitor , and could have received up to one prior line of chemotherapy in the advanced or metastatic setting. [2] 1] [4] It is taken by mouth. [1] 3] [7] PATENTS Cruskie MP, et al.

FDA 62

FDA Pharmacokinetics Therapies Treatment 62

New Drug Approvals

APRIL 25, 2025

15 February 2018). 3] Primary endocrine resistance was defined as relapse while on the first two years of adjuvant endocrine therapy (ET) and secondary endocrine resistance was defined as relapse while on adjuvant ET after at least two years or relapse within twelve months of completing adjuvant ET. [3] doi : 10.1038/ni0403-313.

FDA 57

FDA FDA Approval Therapies Trials 57

Codon

NOVEMBER 3, 2024

Physicians working in the early 20th century had little choice but to treat the world’s most rampant infectious disease with methods such as these. But even now, more than a century later, TB remains the deadliest infectious disease on Earth, killing about 1.2 million people every year.

Vaccine 113

Vaccine Trials Therapies Treatment 113

LifeSciVC

JUNE 12, 2025

Founding Vision: Harnessing RNA Editing for Transformative Medicine Korro Bio’s story began in 2018, co-founded by a remarkable group: Jean-François Formela, M.D. was based on experience building on the understanding that a single protein variant, could have markedly different outcomes for patients with chronic kidney disease.

RNA 67

RNA Protein Expression DNA Science 67

New Drug Approvals

JUNE 15, 2025

Its sodium salt is used for the treatment of generalised myasthenia gravis (a disease that leads to muscle weakness and tiredness) in adults whose immune system produces antibodies against acetylcholine receptors. April 2018). World Health Organization (2018). 4 December 2023. Archived from the original on 11 December 2023.

FDA 57

FDA Treatment Clinical Trials Production 57

The Pharma Data

JUNE 23, 2025

This update is based on robust findings from the STRIDE trial , a landmark study examining the drug’s efficacy in peripheral artery disease (PAD) —a common, debilitating, and often overlooked complication in individuals with type 2 diabetes (T2D). FLOW Trial: The study focused on chronic kidney disease (CKD) in type 2 diabetes patients.

Trials 40

Trials Disease Therapies Treatment 40

BioPharma Drive: Drug Pricing

JULY 16, 2025

On a conference call held Wednesday afternoon, Sarepta CEO Doug Ingram said that "failure to adapt" to recent setbacks "would risk our long-term viability as an organization and decrease the opportunity to bring the greatest benefit to the greatest number of patients living with rare disease." Track how they’re performing.

Therapies 304

Therapies FDA Clinical Trials Licensing 304

National Institute on Drug Abuse: Nora's Blog

NOVEMBER 25, 2024

2 Drug use contributes to the spread of HIV and other infectious diseases like hepatitis B and C in multiple ways, including the sharing of drug injection equipment. According to a 2018 modeling study, at least 127 infections could have been prevented had an SSP opened two years sooner than it did. 2018 Oct;5(10):e569-e577.

Drugs 119

Drugs Treatment Disease Science 119

New Drug Approvals

JULY 8, 2025

HSV in immunocompromised patients Although HSV infection is very common in the general population, it rarely causes serious disease and is effectively contained by the immune system. Infectious Diseases Community of Practice (2013). Infectious Diseases Community of Practice (2009). 2018 Oct 23;9:2483. 2018 Jan;149:1-6.

Virus 62

Virus DNA Clinical Trials Treatment 62

New Drug Approvals

JULY 7, 2025

A number of studies have shown that blocking the CSF-1R signaling pathway could effectively modulate and change macrophage functions, and potentially treat many macrophage-dependent human diseases. [1] 2018-11-29. [2]. Cancer Research, 2018, 78(13_Supplement): LB-288-LB-288. [3]. 6] The U.S. mmol) in methanol (10 mL).

Small Molecule 62

Small Molecule Clinical Trials Licensing Licensing 62

PPD

APRIL 14, 2025

Last year, an American Heart Association presidential advisory for the first time formally identified the strong connections between cardiovascular disease (CVD), kidney disease, Type 2 diabetes and obesity as reason to define cardiovascular-kidney-metabolic (CKM) syndrome.

Clinical Trials 52

Clinical Trials Trials Clinical Development Disease 52

BioPharma Drive: Drug Pricing

JUNE 26, 2025

Permission granted by Incyte Dive Brief: Incyte has named veteran pharmaceutical executive Bill Meury as its new CEO, replacing longtime head Hervé Hoppenot, who led the cancer and blood disease drugmaker for the past 11 years. However, it flamed out in testing in 2018 and Incyte was forced to pivot research toward other candidates.

Licensing 117

Licensing Therapies Licensing Vaccine 117

Science Daily: Pharmacology News

APRIL 29, 2025

Daily exposure to certain chemicals used to make plastic household items could be linked to more than 356,000 global deaths from heart disease in 2018 alone, a new analysis of population surveys shows.

Disease 251

Disease 251

Drugs.com

NOVEMBER 13, 2024

13, 2024 -- Obesity, alcohol use and other factors are driving up rates of fatty liver disease among American adults, new research warns.By 2018, federal data showed that 42% of adults had some form of fatty liver disease -- higher. WEDNESDAY, Nov.

Disease 246

Disease Research 246

Drugs.com

JUNE 13, 2025

FRIDAY, June 13, 2025 — Alcohol-related liver disease deaths are increasing — and they’re rising faster in some groups, including women, young adults and Indigenous people, new research shows.Between 2018 and 2022, deaths from alcohol-associated liv.

Disease 134

Disease Research 134

BioPharma Drive: Drug Pricing

OCTOBER 4, 2024

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

Disease 161

Disease Drugs 161

BioPharma Drive: Drug Pricing

OCTOBER 22, 2024

A medicine the pharma acquired in a $430 million buyout of Visterra in 2018 succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.

Disease 161

Disease Drugs Drug Research Trials 161

BioPharma Drive: Drug Pricing

MARCH 17, 2024

The biotech, formed as a successor to a company Roche acquired in 2018, has two drugs in clinical testing for neurological and immune diseases.

Disease 195

Disease Drugs 195

The Pharma Data

NOVEMBER 17, 2020

17, 2020 — From 2009 to 2018, there were increases in diseases-of-despair diagnoses, according to a study published online Nov. Diagnoses related to alcohol misuse, substance misuse, and suicide ideation/behaviors were defined as diseases of despair. TUESDAY, Nov. 9 in BM J Open. Emily Brignone, Ph.D.,

Disease 52

Disease Virus Research Drugs 52

Drug Target Review

OCTOBER 11, 2023

Almost every one of us will know someone with a neurodegenerative disease such as Alzheimer’s or Parkinson’s. It is less common to know someone with a rare genetic disease; but while individually rare, collectively they have an enormous impact. This will, in turn, slow the progression of, or even halt, the disease.

Disease 113

Disease Treatment Small Molecule Therapies 113

FDA Law Blog: Drug Discovery

JULY 17, 2024

Importantly, the Hub is intended to establish a new model within FDA, which leverages cross-Agency expertise in providing guidance and conducting reviews for products for rare disease populations. Early Direction for the Rare Disease Innovation Hub The Hub, which will be co-chaired by Drs. By Sarah Wicks & James E.

FDA 106

FDA Disease Clinical Pharmacology Science 106

Drug Target Review

JULY 13, 2023

Dewpoint Therapeutics, a platform drug discovery company founded in 2018, has been at the forefront of this exciting field. Dewpoint’s breakthrough was the realisation that certain condensates are associated with human diseases. Klein notes the importance of Dewpoint’s disease-agnostic approach.

Disease 98

Disease Small Molecule Cell Biology Drugs 98

SCIENMAG: Medicine & Health

JUNE 16, 2023

CHICAGO—The percent of metabolic associated fatty liver disease (MAFLD), the leading global cause of liver disease, is increasing in U.S. Mexican Americans consistently had the highest percentage of MAFLD, especially in 2018, although the prevalence of increase […]

Disease 65

Disease 65

BioPharma Drive: Drug Pricing

JULY 22, 2025

An antibody drug, Beyfortus , that Sanofi developed with partner AstraZeneca has become a blockbuster product for preventing RSV disease in infants. This “ molecular clamp ” platform is designed to elicit strong immune responses against respiratory diseases, while permitting simpler and faster production and distribution.

Vaccine 144

Vaccine Clinical Trials FDA Therapies 144

FDA Law Blog: Drug Discovery

DECEMBER 13, 2023

Sasinowski — On December 12, 2023, FDA announced the creation of a new advisory committee specifically for treatments for genetic metabolic diseases, the Genetic Metabolic Diseases Advisory Committee, or “GeMDAC.” There are hundreds of known genetic metabolic diseases, most of which are rare and carry significant morbidity.

Disease 59

Disease Production FDA Drug Development 59

Drug Target Review

NOVEMBER 1, 2023

2 Implication of ATX in a large range of human diseases have been highlighted by both fundamental research and clinical trials. 1-5 Implication of ATX in a large range of human diseases have been highlighted by both fundamental research and clinical trials. 2018 Jun 13;5. 2018 Sep;37(2–3):509–18. Frontiers in Medicine.

Clinical Trials 134

Clinical Trials Trials Small Molecule Disease 134

Drug Target Review

OCTOBER 25, 2024

How does precision neuroscience differ from traditional approaches in the treatment of neurodegenerative diseases, and what advantages does it offer? Traditionally, Alzheimer’s disease is diagnosed by clinical examination, medical history and cognitive testing. We believe we are at a breakthrough moment in Alzheimer’s disease research.

Disease 59

Disease Clinical Trials Therapies Science 59

Conversations in Drug Development Trends

FEBRUARY 28, 2023

95% of rare diseases don’t have a treatment approved and won’t anytime soon. Uplifting Athletes As a 501(c)(3) nonprofit, UA harnesses the power of sport and partnerships with patient advocacy groups to fund the researchers developing datasets for rare diseases that have never been studied or understood before.

Clinical Trials 52

Clinical Trials Disease Trials Research 52

SCIENMAG: Medicine & Health

JUNE 13, 2023

People who adhere to global Cancer Prevention Recommendations are putting themselves at lower risk of developing the disease, new research confirms. Experts at Newcastle University have reviewed evidence of following the 2018 World Cancer Research Fund (WCRF) and American Institute for Cancer Research (AICR) lifestyle-based recommendations.

Disease 82

Disease Research 82

The Pharma Data

NOVEMBER 14, 2020

14, 2020 — Vaping significantly increases the risk of lung disease, according to a new study that adds to growing evidence that e-cigarettes are dangerous. SATURDAY, Nov. Researchers from Boston University analyzed data gathered from more than 21,600 U.S.

Disease 52

Disease Production Research Marketing 52

Advarra

JULY 26, 2022

The 2018 Farm Bill. The 2018 Farm Bill removed hemp from the Controlled Substance Act. Importantly, the 2018 Farm Bill preserved FDA authority to regulate products with cannabis or cannabis-derived compounds under the Federal Food, Drug, and Cosmetic (FD&C) Act and Section 351 of the Public Health Service Act.

Regulations 97

Regulations Research FDA FDA Approval 97

The Pharma Data

DECEMBER 4, 2020

Alzheimer Disease Tied to Adverse Financial Events. 4, 2020 — Alzheimer disease and related dementias (ADRDs) are associated with adverse financial events years prior to clinical diagnosis, according to a study published online Nov. Professional. FRIDAY, Dec. 30 in JAMA Internal Medicine. Lauren Hersch Nicholas, Ph.D.,

Disease 52

Disease International Treatment Research 52

The Pharma Data

AUGUST 24, 2020

AstraZeneca and RenalytixAI have agreed a deal to develop joint precision medicine strategies for cardiovascular, renal and metabolic diseases. The companies will first target chronic kidney disease and use RenaltytixAI’s diagnostic platform, called KidneyIntelX, to examine how to improve patient outcomes.

Disease 52

Disease Clinical Trials Trials 52

LifeSciVC

NOVEMBER 17, 2023

This year we start with a deep dive into the biomedical innovation across our industry – “putting the Big back into Big Pharma” with obesity and Alzheimer’s, and the state of play across other disease areas, industry R&D productivity, and the risks facing the sector. As usual, we close with a brief update on Atlas itself.

Science 107

Science Marketing Production Disease 107

The Pharma Data

OCTOBER 26, 2020

Food and Drug Administration (FDA) has approved EYSUVIS for the short-term treatment of dry eye disease. . adults have been diagnosed with dry eye disease, a chronic, episodic, multifactorial disease. It also increases your risk for inflamed cornea, cornea eye disease, corneal ulcers and injuries, and eye infections. .

Treatment 52

Treatment Disease FDA FDA Approval 52

New Drug Approvals

OCTOBER 12, 2024

Alzheon licensed ALZ-801 from NeuroChem and is developing it for Alzheimer’s disease. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease. 2018; 32(9): 849–861. [2]. 2018 Mar;57(3):315-333. 2007 ; Kocis et al., 2016 ; Abushakra et al., Hey JA, et al. Clin Pharmacokinet.

Pharmacokinetics 62

Pharmacokinetics Small Molecule Disease Licensing 62

Broad Institute

JULY 10, 2023

Credit: Allison Colorado, Broad Communications Arriving in the Bay Area after a childhood in increasingly diverse surroundings, Martin became acutely aware of health disparities and the profound differences in disease prevalence among different populations. I wanted to know how I could have any impact on studying genetic diversity.”

Disease 98

Disease Bioinformatics Medical Schools Research 98